Overview

Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics and Effect on Renal Potassium Clearance

Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the safety and tolerability of LY2623091 after multiple oral dosing in healthy men and women of non-childbearing potential. Two cohorts of 16 subjects will participate in 2 dosing periods. Treatment assignment will be double-blind for LY2623091 and placebo (negative control), and open label for eplerenone (positive control).
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Eplerenone